What question did this study set out to answer?

To explore new strategies for managing melanoma at different stages with a focus on surgical approaches and systemic therapies.

March 18, 2026Academia oncology.Open Access

New paradigms in the management of melanoma throughout various stage of the disease

View Full Paper

Ask AI

Bookmark

To explore new strategies for managing melanoma at different stages with a focus on surgical approaches and systemic therapies.
Evaluated reduced excision margins and sentinel lymph node biopsy usage in early-stage melanoma.
Analyzed the effectiveness of neoadjuvant anti-PD1 therapies in stage III melanoma.
Assessed outcomes from trials like PRADO and MSLT-3 for surgical de-escalation strategies.
Investigated treatment sequences for BRAF mutant patients in advanced melanoma.
Neoadjuvant anti-PD1 therapies showed superior outcomes compared to traditional adjuvant therapies in stage III.
MPR patients may not require additional anti-PD1 treatments for nine months post-surgery.
Dreamseq trial indicated better results when starting with anti-CTLA4 + anti-PD1 for BRAF mutant patients.
A 25–30% overall response rate observed for anti-PD1 refractory treatments using dual therapy.

No takes yet. Share an insight, caveat, or question.

Innovative approaches enhance treatment outcomes for melanoma patients at various disease stages, indicating potential benefits.

Akkooi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark